(Press-News.org) VIDEO:
A coronal mass ejection burst off the side of the sun on May 9, 2014. The giant sheet of solar material erupting was the first CME seen by NASA's Interface...
Click here for more information.
A coronal mass ejection, or CME, surged off the side of the sun on May 9, 2014, and NASA's newest solar observatory caught it in extraordinary detail. This was the first CME observed by the Interface Region Imaging Spectrograph, or IRIS, which launched in June 2013 to peer into the lowest levels of the sun's atmosphere with better resolution than ever before. Watch the movie to see how a curtain of solar material erupts outward at speeds of 1.5 million miles per hour.
IRIS must commit to pointing at certain areas of the sun at least a day in advance, so catching a CME in the act involves some educated guesses and a little bit of luck.
"We focus in on active regions to try to see a flare or a CME," said Bart De Pontieu, the IRIS science lead at Lockheed Martin Solar & Astrophysics Laboratory in Palo Alto, California. "And then we wait and hope that we'll catch something. This is the first clear CME for IRIS so the team is very excited."
The IRIS imagery focuses in on material of 30,000 kelvins at the base, or foot points, of the CME. The line moving across the middle of the movie is the entrance slit for IRIS's spectrograph, an instrument that can split light into its many wavelengths – a technique that ultimately allows scientists to measure temperature, velocity and density of the solar material behind the slit.
The field of view for this imagery is about five Earths wide and about seven-and-a-half Earths tall.
Lockheed Martin Solar & Astrophysics Laboratory designed the IRIS Observatory and manages the mission. NASA's Ames Research Center in Moffett Field, California, provides mission operations and ground data systems. NASA's Goddard Space Flight Center in Greenbelt, Maryland, manages the Explorers Program for NASA's Science Mission Directorate in Washington, D.C.
INFORMATION:
A first for NASA's IRIS: Observing a gigantic eruption of solar material
2014-05-30
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Myriad presents data on BRACAnalysis CDx and HRD at 2014 ASCO meeting
2014-05-30
SALT LAKE CITY, Utah, May 30, 2014 – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics, announced the presentation of new data at the American Society of Clinical Oncology (ASCO) meeting this week that supports the clinical efficacy of its BRACAnalysis CDx™ and HRD™ tests in predicting platinum based therapy response for breast cancer patients. Additionally, the company is providing an update on key commercial milestones that underscore its commitment to the field of companion diagnostics.
"Myriad is committed to advancing the science of companion ...
New method of wormlike motion lets gels wiggle through water
2014-05-30
Next time you spot an earthworm sliding through fresh dirt, take a closer look. What you're seeing is an organic movement called peristaltic locomotion that has been meticulously refined by nature.
Jarod Gregory, an undergraduate student in the University of Cincinnati's College of Engineering and Applied Science, used a worm's contracting and expanding motion to provide a way for gels to swim in water. This is a product of work by the interdisciplinary team consisting of Jarod Gregory, a chemical engineering major, and his two advisers, Lilit Yeghiazarian, assistant ...
New drug treatment helps prevent early menopause in breast cancer patients
2014-05-30
MAYWOOD, Ill. (May 30, 2014) – Among young women treated for breast cancer, one of the most distressing side effects of chemotherapy is early menopause. But a major clinical trial has found that the risk of early menopause can be significantly reduced by adding a drug called goserelin to the chemotherapy regimen. Also, women who took goserelin and wanted to have children were more likely to get pregnant and deliver a healthy baby.
Results were released during the 2014 American Society of Clinical Oncology 50th Annual Meeting in Chicago. Kathy Albain, MD, of Loyola University ...
Stopping statins may benefit terminally ill patients
2014-05-30
Results presented today at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) and June 6 at the European Association of Palliative Care Research Conference show that stopping statins for cholesterol management in the late stages of cancer or other terminal illnesses may offer quality-of-life and even life-extending benefits. The results highlight the larger question of when, if ever, it is appropriate in patients with life-limiting illnesses to discontinue medications prescribed for other conditions that will likely not lead to their death.
Researchers ...
Women with metastatic breast cancer can safely receive bisphosphonates less frequently, without comp
2014-05-30
CHICAGO – Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration. With that practice change, women may also reduce their risk of serious side effects, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.
The research was presented today on the press program of the American Society of Clinical Oncology 2014 Annual Meeting by MD Anderson's Gabriel Hortobagyi, MD, professor, Breast Medical ...
Phase I study of DMOT4039A in patients with pancreatic or ovarian cancer
2014-05-30
A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity.
The drug is in fact a combination of a chemotherapeutic agent with an antibody, technically called an antibody-drug conjugate (ADC). Just as cells ...
Genetic profile predicts which bladder cancer patients will benefit from early chemotherapy
2014-05-30
CHICAGO, IL (May 30, 2014)—Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.
During the study, 36 patients with muscle-invasive bladder cancer received chemotherapy before surgery, consisting of an accelerated regimen of methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC). By the time surgery rolled around, 14 patients appeared cancer-free. ...
For the first time in the lab, researchers see stem cells take key step toward development
2014-05-30
CHAMPAIGN, Ill. — The gap between stem cell research and regenerative medicine just became a lot narrower, thanks to a new technique that coaxes stem cells, with potential to become any tissue type, to take the first step to specialization. It is the first time this critical step has been demonstrated in a laboratory.
University of Illinois researchers, in collaboration with scientists at Notre Dame University and the Huazhong University of Science and Technology in China, published their results in the journal Nature Communications.
"Everybody knows that for an embryo ...
Trial uncovers potential dangers of chemotherapy regimen for bladder cancer patients
2014-05-30
CHICAGO, IL (May 30, 2014)—Patients with muscle-invasive bladder cancer often benefit from chemotherapy before surgery to remove the tumor, but a test of one regimen by researchers at Fox Chase Cancer Center was halted when too many people experienced serious side effects such as heart attacks and blood clots in the legs and lungs.
All of the 31 patients included in the study received a combination of gemcitabine and cisplatin, two drugs normally administered for 12 weeks before surgery to remove the tumors. This became the standard of care after one study looked back, ...
Atomic structure of essential circadian clock protein complex determined
2014-05-30
Structural biologists have made important progress towards better understanding the functioning of the circadian clock. The circadian or inner clock coordinates the sleep-wake rhythm and many other body processes that regulate, for example, metabolism, blood pressure, and the immune system. A research team led by Professor Eva Wolf, recently appointed Professor of Structural Biology at the Institute of General Botany of Johannes Gutenberg University Mainz (JGU) and Adjunct Director at the Institute of Molecular Biology (IMB), has for the first time identified the molecular ...